BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1503 related articles for article (PubMed ID: 20033812)

  • 21. The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer.
    Hong SP; Min BS; Kim TI; Cheon JH; Kim NK; Kim H; Kim WH
    Eur J Cancer; 2012 May; 48(8):1235-43. PubMed ID: 22071131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical overview: adjuvant therapy of gastrointestinal cancer.
    Macdonald JS
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S4-11. PubMed ID: 15309508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.
    Zaanan A; Cuilliere-Dartigues P; Guilloux A; Parc Y; Louvet C; de Gramont A; Tiret E; Dumont S; Gayet B; Validire P; Fléjou JF; Duval A; Praz F
    Ann Oncol; 2010 Apr; 21(4):772-780. PubMed ID: 19833818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.
    Elsaleh H; Powell B; McCaul K; Grieu F; Grant R; Joseph D; Iacopetta B
    Clin Cancer Res; 2001 May; 7(5):1343-9. PubMed ID: 11350904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
    Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
    Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency.
    Jensen LH; Lindebjerg J; Byriel L; Kolvraa S; Crüger DG
    Colorectal Dis; 2008 Jun; 10(5):490-7. PubMed ID: 17868408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer.
    Oh SY; Kim DY; Kim YB; Suh KW
    World J Surg; 2013 Oct; 37(10):2497-503. PubMed ID: 23754140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Multimodal therapy for colon cancer: state of the art].
    Weber T; Link KH
    Zentralbl Chir; 2011 Aug; 136(4):325-33. PubMed ID: 21863510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemoresponsiveness associated with canonical molecular changes in colorectal adenocarcinomas.
    Kim JC; Roh SA; Cho DH; Kim TW; Yoon SN; Kim CW; Yu CS; Kim SY; Kim YS
    Anticancer Res; 2009 Aug; 29(8):3115-23. PubMed ID: 19661324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
    Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
    Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microsatellite instability and DNA mismatch repair deficiency testing in hereditary and sporadic gastrointestinal cancers.
    Gologan A; Sepulveda AR
    Clin Lab Med; 2005 Mar; 25(1):179-96. PubMed ID: 15749237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
    Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM;
    Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
    van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
    J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
    J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemosensitivity and survival in gastric cancer patients with microsatellite instability.
    Oki E; Kakeji Y; Zhao Y; Yoshida R; Ando K; Masuda T; Ohgaki K; Morita M; Maehara Y
    Ann Surg Oncol; 2009 Sep; 16(9):2510-5. PubMed ID: 19565284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microsatellite instability markers for identifying early-onset colorectal cancers caused by germ-line mutations in DNA mismatch repair genes.
    Mead LJ; Jenkins MA; Young J; Royce SG; Smith L; St John DJ; Macrae F; Giles GG; Hopper JL; Southey MC
    Clin Cancer Res; 2007 May; 13(10):2865-9. PubMed ID: 17504984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 76.